1st Faculty of Medicine Charles University Prague Prague Czechia

Centre for Experimental Medicine Institute for Clinical and Experimental Medicine Prague Czechia

Department of Biochemistry and Microbiology University of Chemistry and Technology Prague Czechia

Diabetes Centre Institute for Clinical and Experimental Medicine Prague Czechia

Faculty of Science Charles University Prague Czechia

Institute of Biotechnology Czech Academy of Sciences Prague West Czechia

School of Pharmacy and Medical Science Griffith University Southport QLD Australia

Zobrazit více v PubMed

Bajzikova M, Kovarova J, Coelho AR, Boukalova S, Oh S, Rohlenova K, et al. Reactivation of dihydroorotate dehydrogenase-driven pyrimidine biosynthesis restores tumor growth of respiration-deficient cancer cells. Cell Metab. 2019;29:399–416.e10. PubMed DOI PMC

Copeland WC. The mitochondrial DNA polymerase in health and disease. Subcell. Biochem. 2010;50:211–22. PubMed DOI PMC

Yehudai D, Liyanage SU, Hurren R, Rizoska B, Albertella M, Gronda M, et al. The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase gamma, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia. Haematologica. 2019;104:963–72. PubMed DOI PMC

Chevrollier A, Loiseau D, Reynier P, Stepien G. Adenine nucleotide translocase 2 is a key mitochondrial protein in cancer metabolism. Biochim Biophys. Acta. 2011;1807:562–7. PubMed DOI

Gouriou Y, Alam MR, Harhous Z, Crola Da Silva C, Baetz DB, Badawi S, et al. ANT2-mediated ATP import into mitochondria protects against hypoxia lethal injury. Cells. 2020;9:2542. PubMed DOI PMC

Jang JY, Choi Y, Jeon YK, Kim CW. Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Res. 2008;10:R11. PubMed DOI PMC

Choi Y, Lee HW, Lee J, Jeon YH. The combination of ANT2 shRNA and hNIS radioiodine gene therapy increases CTL cytotoxic activity through the phenotypic modulation of cancer cells: combination treatment with ANT2 shRNA and I-131. BMC Cancer. 2013;13:143. PubMed DOI PMC

Gbolahan OB, Tong Y, Sehdev A, O’Neil B, Shahda S. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. BMC Cancer. 2019;19:468. PubMed DOI PMC

Pebay-Peyroula E, Dahout-Gonzalez C, Kahn R, Trezeguet V, Lauquin GJ, Brandolin G. Structure of mitochondrial ADP/ATP carrier in complex with carboxyatractyloside. Nature. 2003;426:39–44. PubMed DOI

Woyda-Ploszczyca AM. Direct and indirect targets of carboxyatractyloside, including overlooked toxicity toward nucleoside diphosphate kinase (NDPK) and mitochondrial H(+) leak. Pharm. Biol. 2023;61:372–90. PubMed DOI PMC

Jaiquel Baron S, King MS, Kunji ERS, Schirris TJJ. Characterization of drug-induced human mitochondrial ADP/ATP carrier inhibition. Theranostics. 2021;11:5077–91. PubMed DOI PMC

Stemberkova-Hubackova S, Zobalova R, Dubisova M, Smigova J, Dvorakova S, Korinkova K, et al. Simultaneous targeting of mitochondrial metabolism and immune checkpoints as a new strategy for renal cancer therapy. Clin. Transl. Med. 2022;12:e645. PubMed DOI PMC

Bielcikova Z, Stursa J, Krizova L, Dong L, Spacek J, Hlousek S, et al. Mitochondrially targeted tamoxifen in patients with metastatic solid tumours: an open-label, phase I/Ib single-centre trial. EClinicalMedicine. 2023;57:101873. PubMed DOI PMC

Mirza MR, Jakobsen E, Pfeiffer P, Lindebjerg-Clasen B, Bergh J, Rose C. Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. Acta Oncol. 1997;36:171–4. PubMed DOI